WO2001058922A3 - Method and compositions for treating hepatocellular cancer - Google Patents

Method and compositions for treating hepatocellular cancer Download PDF

Info

Publication number
WO2001058922A3
WO2001058922A3 PCT/US2001/004539 US0104539W WO0158922A3 WO 2001058922 A3 WO2001058922 A3 WO 2001058922A3 US 0104539 W US0104539 W US 0104539W WO 0158922 A3 WO0158922 A3 WO 0158922A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha fetoprotein
compositions
hepatocellular cancer
treating hepatocellular
mammal
Prior art date
Application number
PCT/US2001/004539
Other languages
French (fr)
Other versions
WO2001058922A2 (en
WO2001058922A9 (en
Inventor
James S Economou
Lisa H Butterfield
Bruguera Antoni Ribas
Original Assignee
Univ California
James S Economou
Lisa H Butterfield
Bruguera Antoni Ribas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, James S Economou, Lisa H Butterfield, Bruguera Antoni Ribas filed Critical Univ California
Priority to EP01910587A priority Critical patent/EP1253930A4/en
Priority to AU2001238179A priority patent/AU2001238179A1/en
Priority to JP2001558069A priority patent/JP3876162B2/en
Publication of WO2001058922A2 publication Critical patent/WO2001058922A2/en
Publication of WO2001058922A3 publication Critical patent/WO2001058922A3/en
Priority to US10/214,725 priority patent/US7098306B2/en
Publication of WO2001058922A9 publication Critical patent/WO2001058922A9/en
Priority to HK02108331.9A priority patent/HK1046853A1/en
Priority to US11/506,467 priority patent/US20060286075A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464481—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule, where the immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against the cancer cells. A composition for preventing or for treating cancer comprising a peptide having at least part of the sequence of alpha fetoprotein.
PCT/US2001/004539 1997-02-13 2001-02-12 Method and compositions for treating hepatocellular cancer WO2001058922A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01910587A EP1253930A4 (en) 2000-02-10 2001-02-12 Method and compositions for treating hepatocellular cancer
AU2001238179A AU2001238179A1 (en) 2000-02-10 2001-02-12 Method and compositions for treating hepatocellular cancer
JP2001558069A JP3876162B2 (en) 2000-02-10 2001-02-12 Methods and compositions for the treatment of hepatocellular carcinoma
US10/214,725 US7098306B2 (en) 1997-02-13 2002-08-07 Method and compositions for treating hepatocellular cancer
HK02108331.9A HK1046853A1 (en) 2000-02-10 2002-11-18 Method and compositions for treating hepatocellular cancer
US11/506,467 US20060286075A1 (en) 1997-02-13 2006-08-16 Method and compositions for treating hepatocellular cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18196600P 2000-02-10 2000-02-10
US60/181,966 2000-02-10
US66025200A 2000-09-12 2000-09-12
US09/660,252 2000-09-12
US66250500A 2000-09-14 2000-09-14
US09/662,505 2000-09-14

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US66025200A Continuation-In-Part 1997-02-13 2000-09-12
US66250500A Continuation-In-Part 1997-02-13 2000-09-14
US78184401A Continuation 1997-02-13 2001-02-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/214,725 Continuation US7098306B2 (en) 1997-02-13 2002-08-07 Method and compositions for treating hepatocellular cancer

Publications (3)

Publication Number Publication Date
WO2001058922A2 WO2001058922A2 (en) 2001-08-16
WO2001058922A3 true WO2001058922A3 (en) 2002-02-14
WO2001058922A9 WO2001058922A9 (en) 2002-10-17

Family

ID=27391498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004539 WO2001058922A2 (en) 1997-02-13 2001-02-12 Method and compositions for treating hepatocellular cancer

Country Status (7)

Country Link
EP (1) EP1253930A4 (en)
JP (1) JP3876162B2 (en)
KR (1) KR100482920B1 (en)
CN (1) CN1255427C (en)
AU (1) AU2001238179A1 (en)
HK (1) HK1046853A1 (en)
WO (1) WO2001058922A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100985914B1 (en) * 2006-12-13 2010-10-08 주식회사 바이오리더스 Cell Surface Expression Vector for liver Cancer Specific Antigen Alpha-fetoprotein and Microorganism Transformed by Thereof
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
KR100900742B1 (en) * 2007-05-17 2009-06-08 크레아젠 주식회사 Animal Models Carrying Tumors Expressing Human Liver Cancer-Specific Antigen and Method for Analyzing Prevention and Treatment Efficacy of Dendritic Cells-Derived Immunotherapeutics Using the Above
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
SG10201913158PA (en) * 2015-04-03 2020-02-27 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
CN113072636A (en) * 2020-01-06 2021-07-06 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP and its code sequence
CN113321725A (en) * 2020-02-28 2021-08-31 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130415A (en) * 1988-07-29 1992-07-14 Sclavo S.P.A. Synthetic peptide endowed with immunological activity, capable of inducing the production of antibodies with a high specificity towards alpha-fetoprotein, and their use in the diagnostic field
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof
WO1998035981A1 (en) * 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130415A (en) * 1988-07-29 1992-07-14 Sclavo S.P.A. Synthetic peptide endowed with immunological activity, capable of inducing the production of antibodies with a high specificity towards alpha-fetoprotein, and their use in the diagnostic field
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof
WO1998035981A1 (en) * 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BODEY B. ET AL.: "Failure of cancer vaccines: The Significant Limitations of this Approach to Immunetherapy", ANTICANCER RESEARCH, vol. 20, 2000, pages 2665 - 2676, XP002942859 *
BUTTERFIELD L. H. ET AL.: "Identification of a peptide epitope derived from human alpha-fetoprotein (AFP) that elicits cytotoxic T lymphocyte responses against AFP+ tumors", CANCER GENE THERAPY, vol. 5, no. 6, 1998, pages 52 - 53, XP002942863 *
BUTTERFIELD L.H. ET AL.: "Generation of Human T-cell Responses to an HLA-A2.1-restricted Peptide Epitope from alpha-fetoprotein", CANCER RESEARCH, vol. 59, 1 July 1999 (1999-07-01), pages 3134 - 3142, XP002942861 *
CANCER RESEARCH, vol. 59, no. 13, 2000, pages 3064 - 3067 *
DATABASE CANCERLIT [online] 2000, RIBAS A. ET AL.: "Genetic immunotherapy for cancer", XP002942862, Database accession no. 2000257151 *
DATABASE CANCERLIT [online] VOLLMER C. M. JR. ET AL.: "Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma", XP002942860, Database accession no. 1999323374 *
KAMATA Y.: "The prevention of chemical hepatocarcinogenesis in rats by combining active and passive immunization with alpha-fetoprotein", TUMOUR BIOLOGY, vol. 6, 1985, pages 243 - 256, XP002942865 *
ONCOLOGIST, vol. 5, no. 2, 2000, pages 87 - 98 *
TAGA H.: "The effect of active immunization of rats with heterologous alpha-fetoprotein upon hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene", GANN, vol. 74, April 1983 (1983-04-01), pages 248 - 257, XP002942864 *

Also Published As

Publication number Publication date
WO2001058922A2 (en) 2001-08-16
CN1255427C (en) 2006-05-10
WO2001058922A9 (en) 2002-10-17
EP1253930A4 (en) 2003-05-21
EP1253930A2 (en) 2002-11-06
HK1046853A1 (en) 2003-01-30
KR20020073203A (en) 2002-09-19
JP2003522195A (en) 2003-07-22
AU2001238179A1 (en) 2001-08-20
CN1398187A (en) 2003-02-19
JP3876162B2 (en) 2007-01-31
KR100482920B1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2001075087A8 (en) Subtilisin variants
WO2000053722A3 (en) Delivery of nucleic acids and proteins to cells
WO2001058957A3 (en) Enhancing the circulating half-life of antibody-based fusion proteins
WO2000031237A3 (en) Method of cloning porcine animals
WO2007035640A3 (en) Methods for reducing cd36 expression
AU4323599A (en) Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
ID28181A (en) SUBSTRATES TO STOP AND STRENGTHEN DNA, DNA NOT MOVED BY CHIP THAT HAVE DNA WHICH DOES NOT MOVE IN SUBSTRATES, METHOD FOR STRENGTHENING DNA
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
WO2006078899A3 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
AU2284299A (en) Lipopeptides containing an interferon fragment and uses thereof in pharmaceutical compositions
WO2001004282A3 (en) Replication-competent anti-cancer vectors
WO2001025438A3 (en) Ifn-alpha homologues
WO2001058922A3 (en) Method and compositions for treating hepatocellular cancer
WO2001021201A3 (en) Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
WO2002036627A3 (en) Interferons, uses and compositions related thereto
AU4100199A (en) Compositions and methods for enhancing protein anabolism and detoxification
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
AU2002256347A1 (en) Compositions and methods for the identification of protein interactions in vertebrate cells
IL152406A0 (en) Anti-freeze proteins, their production and use
EP1583502A4 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU4910299A (en) Gene and protein involved in liver regeneration
AU2002306645A1 (en) Compositions and methods for increasing amino acid absorption in mammals
WO2000018803A3 (en) Antibodies to mammalian langerhans cell antigen and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001910587

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020027010174

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 558069

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 018047580

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027010174

Country of ref document: KR

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-9, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2001910587

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1020027010174

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 2001910587

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001910587

Country of ref document: EP